Biotech · Public company · Atlanta, GA, US

Alzamend Neuro, Inc.

Ticker ALZN · SEC CIK 0001677077

Track this companyFree. Adds Alzamend Neuro, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials42 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

AL001Phase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
AL001Phase 2 · Bipolar I DisorderClinicalTrials.gov · fetched Nov 12, 2026
ALZN002 (autologous DCs pulsed with E22W mutant peptide).Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Lithium carbonatePhase 2 · Bipolar I DisorderClinicalTrials.gov · fetched Nov 12, 2026
AL001Phase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
Lithium Carbonate CapsulePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderPHASE1_PHASE2 · RECRUITING · started May 11, 2026ClinicalTrials.gov NCT07540338 · fetched Nov 12, 2026
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult SubjectsPHASE1 · COMPLETED · started May 9, 2025ClinicalTrials.gov NCT06921590 · fetched Nov 12, 2026
Study in Subjects With Mild-to-Moderate Alzheimer's DementiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 5, 2023ClinicalTrials.gov NCT05834296 · fetched Nov 12, 2026
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult SubjectsPHASE1_PHASE2 · COMPLETED · started May 4, 2022ClinicalTrials.gov NCT05363293 · fetched Nov 12, 2026